ALT's cash position is a weakness not a strength. And that's a...

ALT's cash position is a weakness not a strength.
And that's a key reason for the low sp v high potential.
There hasn't been any real discussion on cash so I can't see how you conclude many of us are missing the point.
Using your own figures there's not enough cash to last 3rd qtr cy, and receipt of the r&d refund won't be till late 4th qtr.
Last cy was a spp, inov8's contribution, an r&d refund, then another cr already this year. And the Co. has just asked us to renew their placement capacity.
As far as we know the bidding war is still planned for later this year and we might get an upfront large enough to sustain us until b/e, at least 2 years away, more if the lack of sales traction to date is anything to go by. The reason for the auction is ALT doesn't have sufficient cash to adequately market Pericoach so they're going with next best option.
INOV8 is not Peter Corr. It is an arm of the University of Virgin Islands. He runs it with their money.
This is distinct from him investing in ALT via Auven Therapuetics which he's a founding partner of.
Why he hasn't chosen this vehicle is either doubt about viability or more likely Monsour rightly didn't want to relinquish control. Regardless Peter has done due diligence on every aspect of Analytica including the Dr..
Anyway I do agree with your comment 'this is exciting stuff'.